Test ID BLOD0170 Dihydrotestosterone, Serum
Useful For
Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy
Evaluating patients with possible 5-alpha reductase deficiency
Specimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Minimum Volume
0.6 mL
Reject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 90 days | ||
Ambient | 28 days |
Day(s) Performed
Monday, Wednesday, Friday
Report Available
2 to 8 daysMethod Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Portions of this test are covered by patents held by Quest Diagnostics
Performing Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
82642
Reporting Name
Dihydrotestosterone, STesting Algorithm
For more information see Steroid Pathways.
Special Instructions
Reference Values
Males
Cord blood: ≤100 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
Mean |
Age |
Reference range (pg/mL) |
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
Stage II |
12.1 years |
≤200 |
Stage III |
13.6 years |
80-330 |
Stage IV |
15.1 years |
220-520 |
Stage V |
18 years |
240-650 |
>19 years: 112-955 pg/mL
Females
Cord blood: ≤50 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
Mean |
Age |
Reference range (pg/mL) |
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
Stage II |
10.5 years |
≤300 |
Stage III |
11.6 years |
≤300 |
Stage IV |
12.3 years |
≤300 |
Stage V |
14.5 years |
≤300 |
20-55 years: ≤300 pg/mL
>55 years: ≤128 pg/mL
1. Pang S, Levine LS, Chow D, Sagiani F, Saenger P, New MI. Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab. 1979;48(5):821-826
2. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20(2):177-191
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Secondary ID
81479SANFORD INTERFACE BUILD INFORMATION
Result Code | Result Code Description |
---|---|
1319 | Dihydrotestosterone |